Method for detecting autoprocessed, secreted PCSK9
AssigneeMerck Sharp & Dohme Corp.
InventorsAyesha Sitlani, Timothy S. Fisher, Joseph C. Santoro
Life of this patent
Estimating the term…
Loading patent…
AssigneeMerck Sharp & Dohme Corp.
InventorsAyesha Sitlani, Timothy S. Fisher, Joseph C. Santoro
Estimating the term…
The present invention provides a method for detecting autoprocessed, secreted PCSK9, a protein involved in cholesterol homeostasis, and for effectively identifying compounds that inhibit autocleavage and secretion from cells. The disclosed method involves the insertion of an epitope tag into a PCSK9 expression construct immediately C-terminal to the pro domain ending at an amino acid residue corresponding to Q152 of human PCSK9. Upon autoprocessing, the epitope tag is exposed and capable of recognition by anti-epitope antibodies or other suitable identification system, allowing for the selective and exclusive identification and/or quantification of processed PCSK9. The present disclosure thus advances the goal of providing enabling technology to the art for the effective identification of therapeutics effective in combating coronary heart disease.
A method for identifying processed, secreted proprotein convertase subtilisin-kexin type 9 (“PCSK9”) to the exclusion of nonprocessed, secreted PCSK9 in cell supernatant, which comprises:
A method for identifying processed, secreted proprotein convertase subtilisin-kexin type 9 (“PCSK9”) to the exclusion of nonprocessed, secreted PCSK9 in cell supernatant, which comprises:
Dependencies are inferred from the claim text.